Acute Lymphoid Leukemia
Conditions
Interventions
V03.175.500
SP6.270.233.111.534.466
D01.496
This is a longitudinal observational clinical study, with data collection carried out at two moments: before Induction I and after Induction II of treatment. The collection period is approximately 40
Sponsors
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade São Paulo
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade São Paulo
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Participants over 18 years old; both sexes; diagnosed with acute leukemia; treated at the leukemia outpatient clinic of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto (HCFMRP-USP), who will begin high-intensity protocols, designated by the medical team
Exclusion criteria
Exclusion criteria: Patients with cognitive difficulties that make it impossible to understand the study and consent; patients with other associated neoplasms; evidence of infection with human immunodeficiency viruses, hepatitis B or C; women with confirmed pregnancy; evidence or suspicion that the participant will not comply with the requirements of the study protocol; proof or suspicion that the participant is unwilling or unable to understand the information provided in the procedure for obtaining the free and informed consent form; any other factor that, in the opinion of the investigator, may compromise the participant's ability to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Description of possible changes in body composition, energy metabolism, functionality and biochemical parameters of patients undergoing treatment for acute leukemia | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to observe that patients with lower fat-free mass indexes will have lower metabolic rates regardless of the type of leukemia;It is expected to observe that patients using corticosteroids in the induction phase will show a significant increase in fat mass and depletion of muscle mass;It is expected to observe that the toxicity of the treatment favors the loss of muscle mass and functionality and weight variation is related to the type of treatment, not the diagnosis | — |
Countries
Brazil
Contacts
Public ContactThauany Nantes Guirao
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade São Paulo
Outcome results
None listed